Drug Search Results
More Filters [+]

Apratastat

Alternative Names: apratastat, tmi-005, tmi005, tmi 005, xmt-1191, xmt1191, xmt 1191
Latest Update: 2023-03-14
Latest Update Note: PubMed Publication

Product Description

Novel TACE/MMP inhibitor for rheumatoid arthritis

Mechanisms of Action: TNF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Apratastat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-002215-80

P2

Completed

Arthritis, Rheumatoid

2013-01-01

2004-000012-13

P2

Completed

Arthritis, Rheumatoid

2005-08-31

3140A1-200

P2

Completed

Arthritis, Rheumatoid

2005-08-01

Recent News Events